Scholarlink

<p>Cold atmospheric plasma (CAP) has emerged as a promising tool for biomedical applications, including cancer research. In this study, we developed a micro‑sized CAP device designed for minimally painful subdermal plasma delivery in BALB/c mice without the need for anesthesia. The in vitro effects of CAP were evaluated in 4T1 breast cancer cells, and in vivo responses were assessed in tumor‑bearing mice. To quantitatively monitor treatment outcomes, <sup>18</sup>F‑FDG PET imaging was employed to measure metabolic activity and residual tumor burden. CAP‑treated mice demonstrated a measurable reduction in tumor metabolic signal compared with untreated controls. CAP treatment reduced tumor volume in treated animals: in one case, a tumor measuring 40.5&#xa0;mm³ on the treatment day decreased to 0&#xa0;mm³ in the following weeks, and in another case, a 753&#xa0;mm³ tumor was reduced to an elimination point within one week. In contrast, untreated tumors continued to progress to advanced stages. These findings indicate that the proposed device enables effective localized plasma application and supports the potential of CAP–PET as a combined tool for future preclinical theranostic studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting and monitoring cancer cells with cold atmospheric plasma and PET Imaging: a new theranostic approach

  • 期刊论文

  • 发表日期：

    2026年6月26日

查看全文
  • Shokoufeh Karimi,
  • Hasan Mehdian,
  • Shahzad Feizi,
  • Ali Hasanbeigi,
  • Saeed rajabifar

摘要

Cold atmospheric plasma (CAP) has emerged as a promising tool for biomedical applications, including cancer research. In this study, we developed a micro‑sized CAP device designed for minimally painful subdermal plasma delivery in BALB/c mice without the need for anesthesia. The in vitro effects of CAP were evaluated in 4T1 breast cancer cells, and in vivo responses were assessed in tumor‑bearing mice. To quantitatively monitor treatment outcomes, 18F‑FDG PET imaging was employed to measure metabolic activity and residual tumor burden. CAP‑treated mice demonstrated a measurable reduction in tumor metabolic signal compared with untreated controls. CAP treatment reduced tumor volume in treated animals: in one case, a tumor measuring 40.5 mm³ on the treatment day decreased to 0 mm³ in the following weeks, and in another case, a 753 mm³ tumor was reduced to an elimination point within one week. In contrast, untreated tumors continued to progress to advanced stages. These findings indicate that the proposed device enables effective localized plasma application and supports the potential of CAP–PET as a combined tool for future preclinical theranostic studies.